Post by
buddyboybruce on Mar 14, 2022 2:41pm
Therma Bright Awaits FDA-EUA Approval of AcuVid
Therma Bright has been in communication with the FDA since the initial submission of its AcuVid™ COVID-19 Rapid Antigen Saliva Test. Therma has responded to the FDA questions and suggestions and has completed additional documentation and lab tests as required by the FDA.
As we all know, THRM's AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of Care (PoC) has successfully exceeded U.S. Food & Drug Administration's (FDA) Emergency Use Authorization (EUA) requirements for both Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA).
Comment by
TomConstantine on Mar 14, 2022 2:54pm
The process can take years.
Comment by
hk1966 on Mar 14, 2022 3:08pm
And the point is what buddy boy? This is the same crop we've already seen 20 + times in the last 2 months. Nobody gives a flyin you know what. You're not adding anything to this board
Comment by
hk1966 on Mar 15, 2022 7:03pm
You don't say... regurgitating old press release snippets. Meaningless drivel